326 related articles for article (PubMed ID: 22916801)
1. Melatonin in cardiovascular disease.
Dominguez-Rodriguez A
Expert Opin Investig Drugs; 2012 Nov; 21(11):1593-6. PubMed ID: 22916801
[TBL] [Abstract][Full Text] [Related]
2. Evidence that membrane-bound G protein-coupled melatonin receptors MT1 and MT2 are not involved in the neuroprotective effects of melatonin in focal cerebral ischemia.
Kilic U; Yilmaz B; Ugur M; Yüksel A; Reiter RJ; Hermann DM; Kilic E
J Pineal Res; 2012 Mar; 52(2):228-35. PubMed ID: 21913972
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular diseases: protective effects of melatonin.
Tengattini S; Reiter RJ; Tan DX; Terron MP; Rodella LF; Rezzani R
J Pineal Res; 2008 Jan; 44(1):16-25. PubMed ID: 18078444
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular effects of melatonin receptor agonists.
Paulis L; Simko F; Laudon M
Expert Opin Investig Drugs; 2012 Nov; 21(11):1661-78. PubMed ID: 22916799
[TBL] [Abstract][Full Text] [Related]
5. Melatonin receptors as therapeutic targets in the suprachiasmatic nucleus.
Pévet P
Expert Opin Ther Targets; 2016 Oct; 20(10):1209-18. PubMed ID: 27082492
[TBL] [Abstract][Full Text] [Related]
6. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist.
Kato K; Hirai K; Nishiyama K; Uchikawa O; Fukatsu K; Ohkawa S; Kawamata Y; Hinuma S; Miyamoto M
Neuropharmacology; 2005 Feb; 48(2):301-10. PubMed ID: 15695169
[TBL] [Abstract][Full Text] [Related]
7. Docking studies for melatonin receptors.
Alkozi HA; Sánchez Montero JM; Doadrio AL; Pintor J
Expert Opin Drug Discov; 2018 Mar; 13(3):241-248. PubMed ID: 29271261
[TBL] [Abstract][Full Text] [Related]
8. MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.
Liu J; Clough SJ; Hutchinson AJ; Adamah-Biassi EB; Popovska-Gorevski M; Dubocovich ML
Annu Rev Pharmacol Toxicol; 2016; 56():361-83. PubMed ID: 26514204
[TBL] [Abstract][Full Text] [Related]
9. Influence of altered photoperiods on serum melatonin and its receptors (MT1 and MT2) in the brain, retina, and ovary in carp Catla catla.
Moniruzzaman M; Maitra SK
Chronobiol Int; 2012 Mar; 29(2):175-88. PubMed ID: 22324556
[TBL] [Abstract][Full Text] [Related]
10. Photoperiodic regulation of MT1 and MT2 melatonin receptor expression in spleen and thymus of a tropical rodent Funambulus pennanti during reproductively active and inactive phases.
Ahmad R; Haldar C
Chronobiol Int; 2010 May; 27(3):446-62. PubMed ID: 20524795
[TBL] [Abstract][Full Text] [Related]
11. Intracoronary melatonin increases coronary blood flow and cardiac function through β-adrenoreceptors, MT1/MT2 receptors, and nitric oxide in anesthetized pigs.
Grossini E; Molinari C; Uberti F; Mary DA; Vacca G; Caimmi PP
J Pineal Res; 2011 Sep; 51(2):246-57. PubMed ID: 21545522
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the daily changes of melatonin receptors in the rat liver.
Venegas C; García JA; Doerrier C; Volt H; Escames G; López LC; Reiter RJ; Acuña-Castroviejo D
J Pineal Res; 2013 Apr; 54(3):313-21. PubMed ID: 23110416
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic actions of melatonin in cancer: possible mechanisms.
Srinivasan V; Spence DW; Pandi-Perumal SR; Trakht I; Cardinali DP
Integr Cancer Ther; 2008 Sep; 7(3):189-203. PubMed ID: 18815150
[TBL] [Abstract][Full Text] [Related]
14. Pineal and cortical melatonin receptors MT1 and MT2 are decreased in Alzheimer's disease.
Brunner P; Sözer-Topcular N; Jockers R; Ravid R; Angeloni D; Fraschini F; Eckert A; Müller-Spahn F; Savaskan E
Eur J Histochem; 2006; 50(4):311-6. PubMed ID: 17213040
[TBL] [Abstract][Full Text] [Related]
15. Melatonin as an antioxidant: biochemical mechanisms and pathophysiological implications in humans.
Reiter RJ; Tan DX; Mayo JC; Sainz RM; Leon J; Czarnocki Z
Acta Biochim Pol; 2003; 50(4):1129-46. PubMed ID: 14740000
[TBL] [Abstract][Full Text] [Related]
16. Virtual discovery of melatonin receptor ligands to modulate circadian rhythms.
Stein RM; Kang HJ; McCorvy JD; Glatfelter GC; Jones AJ; Che T; Slocum S; Huang XP; Savych O; Moroz YS; Stauch B; Johansson LC; Cherezov V; Kenakin T; Irwin JJ; Shoichet BK; Roth BL; Dubocovich ML
Nature; 2020 Mar; 579(7800):609-614. PubMed ID: 32040955
[TBL] [Abstract][Full Text] [Related]
17. The endogenous melatonin (MT) signal facilitates reentrainment of the circadian system to light-induced phase advances by acting upon MT2 receptors.
Pfeffer M; Rauch A; Korf HW; von Gall C
Chronobiol Int; 2012 May; 29(4):415-29. PubMed ID: 22489607
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in the development of melatonin MT(1) and MT(2) receptor agonists.
Mor M; Rivara S; Pala D; Bedini A; Spadoni G; Tarzia G
Expert Opin Ther Pat; 2010 Aug; 20(8):1059-77. PubMed ID: 20533893
[TBL] [Abstract][Full Text] [Related]
19. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors.
Dubocovich ML; Delagrange P; Krause DN; Sugden D; Cardinali DP; Olcese J
Pharmacol Rev; 2010 Sep; 62(3):343-80. PubMed ID: 20605968
[TBL] [Abstract][Full Text] [Related]
20. MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential.
Zlotos DP; Jockers R; Cecon E; Rivara S; Witt-Enderby PA
J Med Chem; 2014 Apr; 57(8):3161-85. PubMed ID: 24228714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
